Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2473674 | 0.85 | MEN1 (0.65) | MAPK14KMT2AMEN1ALPLMCHR1 | |
| Hydrochloric Acid SCHEMBL9639296 | 0.84 | MEN1 (0.64) | MAPK14KMT2AMEN1ALPLMCHR1 | |
| SCHEMBL2546256 | 0.81 | MAPK14 (0.52) | MAPK14KMT2AMEN1ALPLHPGDS | |
| SCHEMBL3143526 | 0.79 | KMT2A (0.74) | KMT2AMEN1ALPLALDH1A1 | |
| Hydrochloric Acid SCHEMBL9639562 | 0.79 | KMT2A (0.70) | KMT2AMEN1ALPLMCHR1ALDH1A1 | |
| SCHEMBL11687058 | 0.79 | KMT2A (0.74) | KMT2AMEN1ALPLALDH1A1 | |
| SCHEMBL17758514 | 0.79 | MAPK14 (0.56) | MAPK14KMT2AMEN1ALPLHPGDS | |
| Hydrochloric Acid SCHEMBL9639435 | 0.78 | KMT2A (0.72) | KMT2AMEN1ALPLALDH1A1 | |
| SCHEMBL27706504 | 0.78 | ALDH1A1 (0.64) | MAPK14KMT2AMEN1ALPLHPGDS | |
| SCHEMBL458266 | 0.78 | CA1 (0.67) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255100-B2 | Substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-02-09 | — | — | US | disclosed |
| US-9255100-B2 | Substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-02-09 | — | — | US | disclosed |
| EP-2614063-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2614063-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| US-9199999-B2 | Substituted imidazopyrazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9199999-B2 | Substituted imidazopyrazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9199999-B2 | Substituted imidazopyrazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| EP-2576560-B1 | SUBSTITUTED IMIDAZOPYRAZINES | BAYER IP GMBH (DE) | 2015-09-30 | — | — | EP | disclosed |
| EP-2576560-B1 | SUBSTITUTED IMIDAZOPYRAZINES | BAYER IP GMBH (DE) | 2015-09-30 | — | — | EP | disclosed |
| US-20130338133-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-19 | — | — | US | disclosed |
| US-20130210815-A1 | SUBSTITUTED IMIDAZOPYRAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| EP-2614063-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012032031-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032031-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011151259-A1 | SUBSTITUTED IMIDAZOPYRAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210815-A1 | SUBSTITUTED IMIDAZOPYRAZINES | CYP3A5, CYP3A43, HRH2 | MAPK14 4499/4885KMT2A 2221/4885MEN1 679/4885 |
| US-20130338133-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BUB1, TTBK1, BUB1B | MAPK14 646/4885KMT2A 3420/4885MEN1 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.